Cargando…
Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma
Neurofibromatosis type 2 (NF2) is an inherited disorder characterized by bilateral vestibular schwannomas (VS) that arise from neoplastic Schwann cells (SCs). NF2-associated VSs are often accompanied by meningioma (MN), and the majority of NF2 patients show loss of the NF2 tumor suppressor. mTORC1 a...
Autores principales: | Sagers, Jessica E., Beauchamp, Roberta L., Zhang, Yanling, Vasilijic, Sasa, Wu, Limeng, DeSouza, Patrick, Seist, Richard, Zhou, Wenjianlong, Xu, Lei, Ramesh, Vijaya, Stankovic, Konstantina M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060236/ https://www.ncbi.nlm.nih.gov/pubmed/32144278 http://dx.doi.org/10.1038/s41598-020-60156-6 |
Ejemplares similares
-
Identification of Immune-Related Candidate Biomarkers in Plasma of Patients with Sporadic Vestibular Schwannoma: Candidate Plasma Biomarkers in Vestibular Schwannoma
por: Vasilijic, Sasa, et al.
Publicado: (2023) -
New developments in neurofibromatosis type 2 and vestibular schwannoma
por: Ren, Yin, et al.
Publicado: (2020) -
Sporadic Vestibular Schwannoma Size and Location Do not Correlate With the Severity of Hearing Loss at Initial Presentation
por: Brown, Alyssa, et al.
Publicado: (2022) -
Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
por: Sagers, Jessica E., et al.
Publicado: (2018) -
Publisher Correction: Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
por: Sagers, Jessica E., et al.
Publicado: (2018)